Company intelligence / Profile preview
Quercegen Pharmaceuticals
Marlborough, Massachusetts, United Statesquercegen.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Quercegen’s lead program uses a proprietary, high-purity quercetin formulation for chronic obstructive pulmonary disease (COPD) now in Phase II trials, and a next-generation PDI inhibitor, Kinisoquin, in Phase III for cancer-associated thromboembolism; its plant-derived small molecules and formulations are supported by both preclinical and clinical studies showing disease-modifying and safety benefits[1][3][7].
- Therapeutic areas
- OncologyImmunologyCardiovascularPulmonologyHematology
- Modalities
- Small moleculeFlavonoid
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Institutes of Health (NIH)Temple UniversityNational Center for Complementary and Integrative Health (NCCIH)(academic: University of Michigan, others via clinical trial collaborations)
Beyond the preview
Go deeper on Quercegen Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Quercegen Pharmaceuticals.